Home › Castration-Resistant Prostatic Cancer › New Jersey
Castration-Resistant Prostatic Cancer clinical trials in New Jersey
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in New Jersey.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Astera Cancer Care, East Brunswick
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
- Novartis, East Hanover
RecruitingObservational study
Ages 18 to 115 · Men · Updated Jul 16, 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
- Novartis, East Hanover
RecruitingObservational study
Ages 18 to 115 · Men · Updated Jul 16, 2026 · NCT07677254From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.